Bio-Rad Laboratories, Inc.Class A (BIO) Financial Statements
Historical financial data — 40 statements covering FY2018–FY2025
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics...
Bio-Rad Laboratories, Inc.Class A's revenue increased 0.7% year over year, from $2.57B to $2.58B.
Net income increased 141.2% over the same period, from $-1.84B to $759.9M.
Over the 7-year period from FY2018 to FY2025, revenue grew by 13% in total.
Total debt remained relatively stable at $1.20B.
The debt-to-equity ratio stands at 0.16, indicating a conservative leverage profile.
Operating cash flow grew 16.9% to $532.2M.
Bio-Rad Laboratories, Inc.Class A maintains a strong net profit margin of 29.4%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $638.5M+4.5% | $-2.17B | $355.1M | $-2.79B | $97.6M | $9.69B | $1.20B | $6.78B |
| Q3 FY2024 | $649.7M+1.8% | $653.2M | $355.9M | $861.6M | $163.6M | $10.60B | $1.20B | $7.49B |
| Q4 FY2024 | $667.5M+2.7% | $-715.8M | $341.9M | $1.70B | $124.2M | $9.36B | $1.20B | $6.57B |
| Q1 FY2025 | $585.4M-12.3% | $64.0M | $306.0M | $83.4M | $129.9M | $9.53B | $1.20B | $6.68B |
| Q2 FY2025 | $651.6M+11.3% | $317.8M | $345.3M | $414.0M | $116.5M | $10.21B | $1.20B | $7.13B |
| Q3 FY2025 | $653.0M+0.2% | $-341.9M | $343.4M | $-431.1M | $120.9M | $9.70B | $1.20B | $6.74B |
| Q4 FY2025 | $693.2M+6.2% | $720.0M | $345.2M | $-19.1M | $164.9M | $10.58B | $1.20B | $7.45B |
| Q1 FY2026 | $592.1M-14.6% | $-527.1M | $309.4M | $-689.8M | $108.1M | $9.79B | $802.9M | $6.85B |
Balance Sheet Summary (Latest Period)
Bio-Rad Laboratories, Inc.Class A (BIO) Financial Statements & Revenue History
Bio-Rad Laboratories, Inc.Class A (BIO) is a US-listed stock operating in the Technology sector, specifically the Laboratory Analytical Instruments industry trading at $378.00 with a market capitalization of $10. This page provides 40 historical financial statements for Bio-Rad Laboratories, Inc.Class A, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Bio-Rad Laboratories, Inc.Class A reported revenue of $2.6 billion, representing 0.7% year-over-year growth. The net profit margin of 29.4% reflects strong profitability. The debt-to-equity ratio of 0.16 shows conservative leverage.
BIO Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Bio-Rad Laboratories, Inc.Class A's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether BIO is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track BIO's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Bio-Rad Laboratories, Inc.Class A converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of BIO's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use BIO Financial Data
Investors use Bio-Rad Laboratories, Inc.Class A's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare BIO's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how BIO's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View BIO's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Bio-Rad Laboratories, Inc.Class A's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.BIO trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.